CUFinder

Jose Lutzky

Jose Lutzky

University of Miami

H-index: 50

North America-United States

Contact Jose Lutzky

About Jose Lutzky

Jose Lutzky, With an exceptional h-index of 50 and a recent h-index of 33 (since 2020), a distinguished researcher at University of Miami, specializes in the field of clinical trials, cutaneous oncology, melanoma, uveal melanoma.

His recent articles reflect a diverse array of research interests and contributions to the field:

Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

ASO Visual Abstract: Omission of Completion Lymph Node Dissection in Sentinel Node Biopsy Positive Head and Neck Cutaneous Melanoma Patients

703 Single cell analysis of phase II study of nivolumab and relatlimab in metastatic uveal melanoma reveals tumor and immune response to dual PD-1 and LAG-3 inhibition

1534 Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial

Omission of Completion Lymph Node Dissection in Sentinel Node Biopsy Positive Head and Neck Cutaneous Melanoma Patients

1132P Chemokine expression in uveal melanoma and association with tumor genetics and response to immunotherapy

Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238

Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma

Jose Lutzky Information

University

Position

Sylvester Cancer Center

Citations(all)

28058

Citations(since 2020)

11631

Cited By

21391

hIndex(all)

50

hIndex(since 2020)

33

i10Index(all)

98

i10Index(since 2020)

61

Email

University Profile Page

Google Scholar

Jose Lutzky Skills & Research Interests

clinical trials

cutaneous oncology

melanoma

uveal melanoma

Top articles of Jose Lutzky

Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

npj Precision Oncology

2023/11/14

Jun Yin
Jun Yin

H-Index: 24

Jose Lutzky
Jose Lutzky

H-Index: 29

Benjamin Izar
Benjamin Izar

H-Index: 21

ASO Visual Abstract: Omission of Completion Lymph Node Dissection in Sentinel Node Biopsy Positive Head and Neck Cutaneous Melanoma Patients

Annals of surgical oncology

2023/11

Wei Zhao
Wei Zhao

H-Index: 20

Neha Goel
Neha Goel

H-Index: 0

Jose Lutzky
Jose Lutzky

H-Index: 29

703 Single cell analysis of phase II study of nivolumab and relatlimab in metastatic uveal melanoma reveals tumor and immune response to dual PD-1 and LAG-3 inhibition

2023/11/1

Christina Decatur
Christina Decatur

H-Index: 11

Satu Mustjoki
Satu Mustjoki

H-Index: 41

Zelia Correa
Zelia Correa

H-Index: 17

Jose Lutzky
Jose Lutzky

H-Index: 29

1534 Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial

2023/11/1

Jose Lutzky
Jose Lutzky

H-Index: 29

Shailender Bhatia
Shailender Bhatia

H-Index: 39

Rahul Sheth
Rahul Sheth

H-Index: 2

David Geller
David Geller

H-Index: 10

Diwakar Davar
Diwakar Davar

H-Index: 17

Omission of Completion Lymph Node Dissection in Sentinel Node Biopsy Positive Head and Neck Cutaneous Melanoma Patients

Annals of surgical oncology

2023/11

Wei Zhao
Wei Zhao

H-Index: 20

Neha Goel
Neha Goel

H-Index: 0

Jose Lutzky
Jose Lutzky

H-Index: 29

1132P Chemokine expression in uveal melanoma and association with tumor genetics and response to immunotherapy

Annals of Oncology

2023/10/1

Y Shao
Y Shao

H-Index: 20

Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238

New England Journal of Medicine

2017/11/9

Shailender Bhatia
Shailender Bhatia

H-Index: 39

Piotr Rutkowski
Piotr Rutkowski

H-Index: 2

Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma

Journal of cancer research and clinical oncology

2023/8

Jose Lutzky
Jose Lutzky

H-Index: 29

Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM)(CTEP P9466).

2023/6/1

Anita Giobbie-Hurder
Anita Giobbie-Hurder

H-Index: 49

Jose Lutzky
Jose Lutzky

H-Index: 29

A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.

2023/6/1

Benjamin Izar
Benjamin Izar

H-Index: 21

Shailender Bhatia
Shailender Bhatia

H-Index: 39

Diwakar Davar
Diwakar Davar

H-Index: 17

Jose Lutzky
Jose Lutzky

H-Index: 29

Can exosomal cargoes predict checkpoint inhibitor response in melanoma, and can we overcome drug resistance

Cancer Research

2023/4/4

Dan Nguyen
Dan Nguyen

H-Index: 21

Medhi Wangpaichitr
Medhi Wangpaichitr

H-Index: 19

Stephane Roche
Stephane Roche

H-Index: 14

Jose Lutzky
Jose Lutzky

H-Index: 29

Neha Goel
Neha Goel

H-Index: 0

Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 …

JAMA oncology

2023/1/1

Steven Brem
Steven Brem

H-Index: 28

Kevin Lillehei
Kevin Lillehei

H-Index: 25

Jose Lutzky
Jose Lutzky

H-Index: 29

David Mathieu
David Mathieu

H-Index: 32

Michel Lacroix
Michel Lacroix

H-Index: 4

CTIM-27. autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent glioblastoma: survival results from a phase …

Neuro-Oncology

2022/11/1

Steven Brem
Steven Brem

H-Index: 28

Robert Aiken
Robert Aiken

H-Index: 11

Daniela Bota
Daniela Bota

H-Index: 26

Kevin Lillehei
Kevin Lillehei

H-Index: 25

Andrew Brenner
Andrew Brenner

H-Index: 5

Jose Lutzky
Jose Lutzky

H-Index: 29

787 DELTA-1: a global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced …

2022/11/1

Anthony Olszanski
Anthony Olszanski

H-Index: 28

Jose Lutzky
Jose Lutzky

H-Index: 29

Thomas Evans
Thomas Evans

H-Index: 10

Daniel Olson
Daniel Olson

H-Index: 28

Robert Hawkins
Robert Hawkins

H-Index: 42

Yizhou Jiang
Yizhou Jiang

H-Index: 16

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy

Frontiers in oncology

2022/8/29

Shaheer Khan
Shaheer Khan

H-Index: 0

Jose Lutzky
Jose Lutzky

H-Index: 29

Manpreet S Katari
Manpreet S Katari

H-Index: 14

Oliver Surriga
Oliver Surriga

H-Index: 3

Recognising immunotherapy-induced meningoencephalitis: a case during treatment for primary metastatic melanoma of the bladder neck

BMJ Case Reports CP

2022/7/1

Jose Lutzky
Jose Lutzky

H-Index: 29

Molecular and immunologic characterization of HRAS mutations in a cohort of 6,329 patients with cutaneous melanoma

2022/6/15

Jun Yin
Jun Yin

H-Index: 24

Jose Lutzky
Jose Lutzky

H-Index: 29

Gilberto Lopes
Gilberto Lopes

H-Index: 35

Comprehensive genomic and transcriptomic profiling of acral lentiginous melanoma

2021/5/20

Daniel H Hovelson
Daniel H Hovelson

H-Index: 23

A randomized, controlled, open-label, phase 2 study of cemiplimab±RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).

2022/6/1

Jose Lutzky
Jose Lutzky

H-Index: 29

Muhammad Alamgeer
Muhammad Alamgeer

H-Index: 10

Optimization of Voyager V1 (VV1) oncolytic virus systemic delivery in combination with cemiplimab and ipilimumab in patients with melanoma and non–small cell lung cancer (NSCLC).

2022/6/1

Jose Lutzky
Jose Lutzky

H-Index: 29

Manish Patel
Manish Patel

H-Index: 1

See List of Professors in Jose Lutzky University(University of Miami)